Neurochemical Research

, Volume 41, Issue 12, pp 3239–3249 | Cite as

Possible Mechanisms Involved in Attenuation of Lipopolysaccharide-Induced Memory Deficits by Methyl Jasmonate in Mice

  • Anthony Taghogho Eduviere
  • Solomon Umukoro
  • Olusegun A. Adeoluwa
  • Itivere Adrian Omogbiya
  • Oritoke Modupe Aluko
Original Paper


This present study was carried out to investigate the likely mechanisms by which methyl jasmonate (MJ), ‘an agent widely used in aromatherapy for neurological disorders, attenuates lipopolysaccharide (LPS)-induced memory deficits in mice. Mice were given intraperitoneal administration of LPS (250 µg/kg) alone or in combination with MJ (10–40 mg/kg), donepezil, DP (1 mg/kg), or vehicle for 7 successive days. Thereafter, memory was assessed using object recognition test (ORT). Acetylcholinesterase and myeloperoxidase activities were estimated in brain tissue homogenates. Brain levels of nitric oxide and markers of oxidative stress as well as histopathologic changes of the prefrontal cortex and cornu ammonis 1 (CA1) of the hippocampal region were also assessed. MJ (10–40 mg/kg) attenuated LPS-induced memory impairment in ORT. Moreover, the increased brain activities of acetylcholinesterase and myeloperoxidase enzymes were suppressed by MJ when compared with control (p < 0.05). Increased brain oxidative stress and nitric oxide levels in LPS-treated mice were significantly decreased by MJ. It offers protection against LPS-induced neuronal degeneration of the prefrontal cortex and CA1 of the hippocampus, suggesting neuroprotective effect. Taken together, these findings showed that MJ offers protection against LPS-induced memory deficits via mechanisms related to inhibition of acetylcholinesterase, myeloperoxidase, oxidative stress and neuronal degeneration.


Methyl jasmonate Memory impairment Neuroinflammation Lipopolysaccharide 



Authors thanked the technical staff of the Department of Pharmacology and Therapeutics for their assistance. We also appreciate Professors E.A. Bababumi and O.G. Ademowo for introducing methyl jasmonate to us.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interests.


  1. 1.
    Cesari IM, Carvalho E, Rodrigues MF, Mendonça BS, Amôedo ND, Rumjanek FD (2014) Methyl jasmonate: putative mechanisms of action on cancer cells cycle, metabolism, and apoptosis. Int J Cell Biol 2014:1–25CrossRefGoogle Scholar
  2. 2.
    Bowles DJ (1990) Defense-related proteins in higher plant. Ann Rev Biochemistr 59:873–907CrossRefGoogle Scholar
  3. 3.
    Belsito DD, Bickers M, Bruze P, Calow M, Dagli AD, Fryer H, Greim JH, HanifinY, Miyachi JH, Saurat IG (2012) Sipes, Toxicologic and dermatologic assessment ofcyclopentanones and cyclopentenones when used as fragrance ingredients. Food Chem Toxicol 50:S572–S576CrossRefGoogle Scholar
  4. 4.
    Hossain SJ, Aoshima H, Corda H, KisoY (2004) Fragrances in oolong that enhance the response of GABAA receptors. Biosci Biochnol Biochem 68:1242–1248Google Scholar
  5. 5.
    Umukoro S, Eduviere AT, Aladeokin AC (2012) Anti-aggressive activity of methyl jasmonate and the probable mechanism of its action in mice. Pharmacol Biochem Behav 101:271–277CrossRefPubMedGoogle Scholar
  6. 6.
    Umukoro S, Alabi AO, Aladeokin AC (2011) Antidepressant activity of methyl jasmonate, a plant stress hormone in mice. Pharmacol Biochem Behav 98:8–11CrossRefPubMedGoogle Scholar
  7. 7.
    Umukoro S, Olugbemide AS (2011) Antinociceptive effects of methyl jasmonate in experimental animals. J Nat Med 65:466–470CrossRefPubMedGoogle Scholar
  8. 8.
    Lee JW, Lee YK, Yuk DY, Choi DY, Ban SB, Oh KW, Hong JT (2008) Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of Beta-Amyloid generation. J Neuroinflamm 5:37CrossRefGoogle Scholar
  9. 9.
    Frühauf PKS, Ineu RP, Tomazi L, Duarte T, Mello CF, Rubin MA (2015) Spermine reverses lipopolysaccharide-induced memory deficit in mice. J Neuroinflammation 12:1–11. doi: 10.1186/s12974-014-0220-5 CrossRefGoogle Scholar
  10. 10.
    Houdek HM, Larson J, Watt JA, Rosenberger TA (2014) Bacterial lipopolysaccharide induces a dose-dependent activation of neuroglia and loss of basal forebrain cholinergic cells in the rat brain. Inflamm Cell Signal 1:e47. doi: 10.14800/ics.47 PubMedPubMedCentralGoogle Scholar
  11. 11.
    Czerniawski J, Miyashita T, Lewandowski G, Guzowski JF (2015) Systemic lipopolysaccharide administration impairs retrieval of context-object discrimination, but not spatial, memory: evidence for selective disruption of specific hippocampus-dependent memory functions during acute neuroinflammation. Brain Behav Immun 44:159–166CrossRefPubMedGoogle Scholar
  12. 12.
    Ming Z, Wotton CA, Appleton RT, Ching JC, Loewen ME, Sawicki G, Bekar LK (2015) Systemic lipopolysaccharide-mediated alteration of cortical neuromodulation involves increases in monoamine oxidase-A and acetylcholinesterase activity. J Neuroinflammation 12:37–47CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Markesbery WR (1997) Oxidative stress hypothesis in Alzheimer’s disease. Free Radic Biol Med 23:134–147CrossRefPubMedGoogle Scholar
  14. 14.
    Potter PE (2013) Curcumin: a natural substance with potential efficacy in Alzheimer’s disease. J Exp Pharmacol 5:23–31CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Moreira PI, Santos MS, Oliveira CR, Shenk JC, Nunomura A, Smith MA, Zhu X, Perry G (2008) Alzheimer disease and the role of free radicals in the pathogenesis of the disease. CNS Neurol Disord Drug Targ 7:3–10CrossRefGoogle Scholar
  16. 16.
    Myhrer T (2003) Neurotransmitter systems involved in learning and memory in the rat: a meta-analysis based on studies of four behavioral tasks. Brain Research Review 41(2–3):268–287CrossRefGoogle Scholar
  17. 17.
    Terry AW, Buccafusco JJ (2003) The cholinergic hypothesis of age and Alzheimer’s disease-related cognitive deficits: recent challenges and their implications for novel drug development. J Pharmacol Exp Ther 306:821–827CrossRefPubMedGoogle Scholar
  18. 18.
    Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS (2009) Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther 1:7CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Hsieh MT, Peng WH, Wu CR, Ng KY, Cheng CL, Xu HX (2010) Review on experimental research of herbal medicines with anti-amnesic activity. Planta Med 76:203–217CrossRefPubMedGoogle Scholar
  20. 20.
    Uttara B, Singh AW, Zamboni P, Mahajan RT (2009) Oxidative stress and neurodegenerative diseases: a review of upstream and downstream antioxidant therapeutic options. Curr Neuropharmacol 7:65–74CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Eduviere AT, Umukoro S, Aderibigbe AO, Ajayi AM, Adewole FA (2015) Methyl jasmonate enhances memory performance through inhibition of oxidative stress and acetylcholinesterase activity in mice. Life Sci 132:20–26CrossRefPubMedGoogle Scholar
  22. 22.
    Klinkenberg I, Blokland A (2010) The validity of scopolamine as a pharmacological model for cognitive impairment: a review of animal behavioral studies. Neurosci Biobehav Rev 34:1307–1350CrossRefPubMedGoogle Scholar
  23. 23.
    Deng XH, Li M, Ai W, He L, Lu D, Patrylo PR, Cai H, Luo X, Li ZX, Yan X-X (2014) Lipolysaccharide-induced neuroinflammation is associated with Alzheimer-like amyloidogenic axonal pathology and dendritic degeneration in rats. Advances Alzheimer’s Disease 3:78–93CrossRefGoogle Scholar
  24. 24.
    Taglialatela G, Hogan D, Zhang WR, Dineley KT (2009) Intermediate-and long-term recognition memory deficits in Tg2576 mice are reversed with acute calcineurin inhibition. Behav Brain Res 200:95–99CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Ellman GL, Courtney KD, Andre JV, Featherstone RM (1961) A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 7:88–95CrossRefPubMedGoogle Scholar
  26. 26.
    Moron MS, Depierre JW, Mannervik B (1979) Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta 582:67–78CrossRefPubMedGoogle Scholar
  27. 27.
    Adam-Vizi A, Seregi V (1982) Receptor independent stimulatory effect of noradrenaline on Na+/K+-ATPase in rat brain homogenate, role of lipid peroxidation. Biochem Pharmacol 34:2231–2236CrossRefGoogle Scholar
  28. 28.
    Misra HP, Fridovich I (1972) The role of superoxide anion in the autooxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 247:3170–3175PubMedGoogle Scholar
  29. 29.
    Sinha KA (1971) Colorimetric assay of catalase. Anal Biochem 47:389–394CrossRefGoogle Scholar
  30. 30.
    Bradley PP, Priebat DA, Christensen RD, Rothstein G (1982) Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78:206–209CrossRefPubMedGoogle Scholar
  31. 31.
    Green LC, Wagner DA, Glogowski J et al (1982) Analysis of nitrate, nitrite, and [15N] nitrate in biological fluids. Anal Biochem 126:131–138CrossRefPubMedGoogle Scholar
  32. 32.
    Gornall AG, Bardawill CJ, David MM (1949) Determination of serum protein bymeans of biuret reaction. J Biol Chem 177:751–766PubMedGoogle Scholar
  33. 33.
    Eltony SA, Elgayar SA (2014) Histological study on effect of Nigella sativa on aged olfactory system of female albino rat. Rom J Morphol Embryol 55:325–334PubMedGoogle Scholar
  34. 34.
    Going JJ (1994) Efficiently estimated histologic cell counts. Hum Pathol 25:333–336CrossRefPubMedGoogle Scholar
  35. 35.
    Anaeigoudari A, Shafei MN, Soukhtanloo M, Sadeghnia HR, Reisi R, Beheshti F, Mohebbati R, Mousavi SM, Hosseini M (2015) Lipopolysaccharide-induced memory impairment in rats is preventable using 7-nitroindazole. Arq Neuropsiquiatr 73:784–790CrossRefPubMedGoogle Scholar
  36. 36.
    Ennaceur A (2010) One-trial object recognition in rats and mice: methodological and theoretical issues. Behav Brain Res 215:244–254CrossRefPubMedGoogle Scholar
  37. 37.
    Kraft AD, Harry GJ (2011) Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity. Int J Environ Res Public Health 8:2980–3018CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Loria V, Dato I, Graziani F, Biasucci LM (2008) Myeloperoxidase: a new biomarker of inflammation in ischemic heart disease and acute coronary syndromes. Mediators Inflamm 4. doi: 10.1155/2008/135625 (Article ID 135625)
  39. 39.
    Willard LB, Hauss-wegrzniak B, Danysz W, Wenk GL (2000). The cytotoxicity of chronic neuroinflammation upon basal forebrain cholinergic neurons of rats can be attenuated by glutamatergic antagonism or cyclooxygenase-2 inhibition. Exp Brain Res 134:58–65CrossRefPubMedGoogle Scholar
  40. 40.
    Semmler A, Frisch C, Debeir T, Ramanathan M, Okulla T, Klockgether T, Heneka MT (2007) Long-term cognitive impairment, neuronal loss and reduced cortical cholinergic innervation after recovery from sepsis in a rodent model. Exp Neurol 204:733–740Google Scholar
  41. 41.
    Block ML, Zecca L, Hong JS (2007) Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 8:57–69CrossRefPubMedGoogle Scholar
  42. 42.
    Maki RA, Tyurin VA, Lyon RC, Hamilton RL, DeKosky ST, Kagan VE, Reynolds WF (2009) Aberrant expression of myeloperoxidase in astrocytes promotes phospholipid oxidation and memory deficits in a mouse model of Alzheimer disease. J Biol Chem 284:3158–3169CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    Kubota K, Saiwai H, Kumamaru H, Maeda T, Ohkawa Y, Aratani Y, Nagano T, Iwamoto Y, Okada S (2012) Myeloperoxidase exacerbates secondary injury by generating highly reactive oxygen species and mediating neutrophil recruitment in experimental spinal cord injury. Spine (Phila Pa 1976) 37:1363–1369CrossRefGoogle Scholar
  44. 44.
    Gilgun-Sherki Y, Melamed E, Offen D (2003) Antioxidant treatment in Alzheimer’s disease: current state. J Mol Neurosci 21:1–11CrossRefPubMedGoogle Scholar
  45. 45.
    Natalie A, Kelsey I, Heather M, Wilkins I, Linseman DA (2010) Nutraceutical antioxidants as novel neuroprotective agents. Molecules 15:7792–7814CrossRefGoogle Scholar
  46. 46.
    Bejar C, Wang RH, Weinstock M (1999) Effect of rivastigmine on scopolamine induced memory impairment in rats. Eur J Pharmacol 383:231–240CrossRefPubMedGoogle Scholar
  47. 47.
    Tyagi E, Agrawal R, Nath C, Shukla R (2008) Influence of LPS-induced neuroinflammation on acetylcholinesterase activity in rat brain. J Neuroimmunol 205:51–56CrossRefPubMedGoogle Scholar
  48. 48.
    Environmental Protection Agency (EPA) (2013) Methyl jasmonate: exemption from the requirement of a tolerance. Fed Regist 78:22789–22794Google Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Anthony Taghogho Eduviere
    • 1
    • 2
  • Solomon Umukoro
    • 1
  • Olusegun A. Adeoluwa
    • 2
  • Itivere Adrian Omogbiya
    • 3
  • Oritoke Modupe Aluko
    • 4
  1. 1.Neuropharmacology unit, Department of Pharmacology and TherapeuticsCollege of Medicine, University of IbadanIbadanNigeria
  2. 2.Department of Pharmacology and TherapeuticsCollege of Medicine and Health Sciences, Afe Babalola UniversityAdo-EkitiNigeria
  3. 3.Department of Pharmacology and TherapeuticsCollege of Health Sciences, Delta State UniversityAbrakaNigeria
  4. 4.Department of Pharmacology and TherapeuticsCollege of Health Sciences, Bowen UniversityIwoNigeria

Personalised recommendations